Literature DB >> 1533726

Model-based screening by risk with application to Down's syndrome.

P Royston1, S G Thompson.   

Abstract

Screening for a disorder may be carried out by assessing the risk that an individual is affected given the values of variables whose distributions alter when the disorder is present. An optimal screening policy is obtained by identifying those individuals whose risk is greater than some cut-off value. This paper summarizes the way in which risk is derived from the likelihood ratio of being affected by the disorder, and compares three different methods of estimating the likelihood ratio, namely direct estimation, logistic regression and distribution modelling. For continuous variables that have a multivariate normal distribution, screening by risk is equivalent to the use of quadratic discrimination. The paper shows how estimates of the risk and associated detection and false positive rates can be derived for a screening policy which uses specified risk cut-offs. Screening by risk has the counter-intuitive property that as the separation in the distribution of screening variables between affected and unaffected individuals increases, the detection and false positive rates may both increase. The approach is explored using data on antenatal screening for Down's syndrome. The method of choice is model-based; the model is described and tested for goodness of fit. Complications arising from outliers and non-normality must be overcome before an appropriate assessment of risk can be made. The concept of shrinkage is used to estimate the detection of false positive rates that may be expected in a new data set.

Entities:  

Mesh:

Year:  1992        PMID: 1533726     DOI: 10.1002/sim.4780110211

Source DB:  PubMed          Journal:  Stat Med        ISSN: 0277-6715            Impact factor:   2.373


  10 in total

Review 1.  Rational Down syndrome screening policy.

Authors:  H Cuckle
Journal:  Am J Public Health       Date:  1998-04       Impact factor: 9.308

2.  A risk model of prenatal screening markers in first trimester for predicting hypertensive disorders of pregnancy.

Authors:  Yiming Chen; Zhen Xie; Xue Wang; Qingxin Xiao; Xiao Lu; Sha Lu; Yezhen Shi; Shaolei Lv
Journal:  EPMA J       Date:  2020-06-19       Impact factor: 6.543

3.  Role of second-trimester genetic sonography after Down syndrome screening.

Authors:  Kjersti M Aagaard-Tillery; Fergal D Malone; David A Nyberg; T Flint Porter; Howard S Cuckle; Karin Fuchs; Lisa Sullivan; Christine H Comstock; George R Saade; Keith Eddleman; Susan Gross; Lorraine Dugoff; Sabrina D Craigo; Ilan E Timor-Tritsch; Stephen R Carr; Honor M Wolfe; Diana W Bianchi; Mary E D'Alton
Journal:  Obstet Gynecol       Date:  2009-12       Impact factor: 7.661

4.  Interpreting the concordance statistic of a logistic regression model: relation to the variance and odds ratio of a continuous explanatory variable.

Authors:  Peter C Austin; Ewout W Steyerberg
Journal:  BMC Med Res Methodol       Date:  2012-06-20       Impact factor: 4.615

5.  Adding free to total prostate-specific antigen levels in trials of prostate cancer screening.

Authors:  N J Wald; H C Watt; L George; P Knekt; K J Helzlsouer; J Tuomilehto
Journal:  Br J Cancer       Date:  2000-02       Impact factor: 7.640

6.  Predicting Hypertensive Disease in the First Trimester of Pregnancy: Risk Models and Analysis of Serum D-dimer Levels Combined with Plasma Pregnancy-Associated Protein A, Free β-Subunit of Human Chorionic Gonadotropin, and Fetal Nuchal Translucency.

Authors:  Yiming Chen; Wenwen Ning; Xuelian Chu; Yijie Chen; Linyuan Gu; Zhen Xie; Liyao Li; Caihe Wen; Xiaoying Wang
Journal:  Biomed Res Int       Date:  2022-03-30       Impact factor: 3.411

7.  A Risk Model for Predicting Fetuses with Trisomy 21 Using Alpha-Fetoprotein Variants L2 Combined with Maternal Serum Biomarkers in Early Pregnancy.

Authors:  Yiming Chen; Bin Wu; Yijie Chen; Wenwen Ning; Huimin Zhang
Journal:  Reprod Sci       Date:  2021-11-08       Impact factor: 3.060

8.  Diagnostic value of maternal alpha-fetoprotein variants in second-trimester biochemical screening for trisomy 21 and 18.

Authors:  Yiming Chen; Yijie Chen; Wenwen Ning; Wen Zhang; Liyao Li; Xiaoying Wang; Yixuan Yin; Huimin Zhang
Journal:  Sci Rep       Date:  2022-08-10       Impact factor: 4.996

Review 9.  Prenatal Screening Using Maternal Markers.

Authors:  Howard Cuckle
Journal:  J Clin Med       Date:  2014-05-09       Impact factor: 4.241

10.  Correcting for optimistic prediction in small data sets.

Authors:  Gordon C S Smith; Shaun R Seaman; Angela M Wood; Patrick Royston; Ian R White
Journal:  Am J Epidemiol       Date:  2014-06-24       Impact factor: 4.897

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.